Axogen, Inc. — Director's Dealing 2018

Dec 5, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AxoGen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2018-11-30

Reporting Person: Freitag Gregory Gene (Director, General Counsel)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-11-30	Common Stock	S	45000	$33.00	Disposed	95865	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan (the "Plan") adopted by the reporting person on September 7, 2018, as amended November 9, 2018. The sales resulted in the completion of the Plan so no more shares will be sold pursuant to the Plan.

F2: The price reported is the actual sale price for all of these shares that were sold in multiple transactions. The reporting person undertakes to provide to AxoGen, Inc., any security holder of AxoGen, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the sale of the shares.